Biologics in Plaque Psoriasis

An assessment of the current reimbursement of biologics used to treat adults with moderate-to-severe plaque psoriasis (PsO) is needed given the significant expenditures on biologics and the changing dynamics because of loss of exclusivity and new-generation biologic entrants. This Environmental Scan assessed the regulatory, exclusivity, Canada's Drug Agency review, and reimbursement status of biologics for PsO relevant to public drug plans.

There is significant utilization of old-generation originators in new claimants despite the availability of new-generation biologics which have direct comparative evidence to support superiority. Marketing of old-generation biosimilars has been delayed for more than 3 years, and several old-generation biologics have no biosimilar versions available despite loss of exclusivity.

Old-generation originators largely predate the pCPA process, thus their reimbursement is less likely to be associated with a listing agreement. Overall, formulary management strategies could be employed for payers to optimize patient outcomes.